関連文献

Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.

Eur J Pharmacol. 2017PubMed

Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.

Clin Exp Hypertens. 2017PubMed

Urine liver fatty acid binding protein and chronic kidney disease progression.

Scand J Clin Lab Invest. 2017PubMed

Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.

Diabetologia. 2017 PubMed

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.

JClin Med Res. 2017PubMed

Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.

Nephrology. 2017PubMed

The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.

Clin Exp Nephrol. 2016PubMed

Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.

FASEB J. 2016PubMed

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.

Cardiovasc Diabetol. 15(1): 76, 2016.PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed